2. Search Result
Search Result
Pathways Recommended: Immunology/Inflammation
Results for "

cancer immunology

" in MedChemExpress (MCE) Product Catalog:

2781

Inhibitors & Agonists

2

Screening Libraries

15

Fluorescent Dye

30

Biochemical Assay Reagents

96

Peptides

130

Inhibitory Antibodies

1087

Natural
Products

196

Isotope-Labeled Compounds

13

Click Chemistry

36

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131967
    CD73-IN-4

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD73-IN-4
  • HY-156569
    DGKα-IN-2

    		DGK Inflammation/Immunology Cancer
    DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-2
  • HY-78131C
    Ibuprofen sodium
    10+ Cited Publications

    (±)-Ibuprofen sodium

    		 COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen sodium
  • HY-78131
    Ibuprofen
    10+ Cited Publications

    (±)-Ibuprofen

    		 COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen
  • HY-100586
    Ibuprofen L-lysine
    10+ Cited Publications

    (±)-Ibuprofen L-lysine

    		 COX Apoptosis Parasite Infection Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) L-lysine is a potent orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen L-lysine inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen L-lysine is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen L-lysine can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen L-lysine
  • HY-78131S2
    Ibuprofen-d4

    		Apoptosis COX Parasite Cancer
    Ibuprofen-d4 is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[2][3][4][5].
    Ibuprofen-d4
  • HY-147283
    MK2-IN-4

    		MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC50 value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .
    MK2-IN-4
  • HY-156570
    DGKα-IN-3

    		DGK Inflammation/Immunology Cancer
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-149411
    IDO1/TDO-IN-6

    		Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    IDO1/TDO-IN-6 (compound 11) is a dual inhibitor of IDO1/TDO with IC50s of 2.25 and 2.89 μM, respectively. IDO1/TDO-IN-6 has inhibitory effects on IDO1 and TDO, with Ki values of 1.9 and 3.1 μM, respectively. IDO1/TDO-IN-6 can be used in cancer and immunology research .
    IDO1/TDO-IN-6
  • HY-78131R
    Ibuprofen (Standard)

    		COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen (Standard) is the analytical standard of Ibuprofen. This product is intended for research and analytical applications. Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen (Standard)
  • HY-P9902
    Pembrolizumab
    10+ Cited Publications

    MK-3475; Lambrolizumab

    		 PD-1/PD-L1 Cancer
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    Pembrolizumab
  • HY-156571
    DGKα-IN-4

    		DGK Cancer
    DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
    DGKα-IN-4
  • HY-135890
    CG347B
    2 Publications Verification

    		 HDAC Neurological Disease Inflammation/Immunology Cancer
    CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research .
    CG347B
  • HY-78131S3
    Ibuprofen-13C6

    (±)-Ibuprofen-13C6

    		 Isotope-Labeled Compounds Cancer
    Ibuprofen- 13C6 ((±)-Ibuprofen- 13C6) is a 13C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen-13C6
  • HY-156415
    NLRP3 agonist 2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3 agonist 2 (compound 22) is a orally active NLRP3 agonist.NLRP3 agonist 2 activates Caspase-1 in THP1 cells .
    NLRP3 agonist 2
  • HY-151093
    IDO2-IN-1
    1 Publications Verification

    		 Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology
    IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research .
    IDO2-IN-1
  • HY-153245
    JNJ-64264681

    		Btk Inflammation/Immunology Cancer
    JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 exhibits good pharmacokinetic characteristics and can be used for cancer and autoimmune diseases research .
    JNJ-64264681
  • HY-149992
    MyD88-IN-1

    		MyD88 Inflammation/Immunology Cancer
    MyD88-IN-1 (Compound c17) is an orally active MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory .
    MyD88-IN-1
  • HY-30235
    Benzydamine

    		PGE synthase TNF Receptor Bacterial Inflammation/Immunology Cancer
    Benzydamine is an orally administered prostaglandin synthesis inhibitor that has anti-inflammatory, analgesic, antipyretic, and antibacterial properties. Benzydamine can inhibit TNF-α, stabilize cell membranes, and reduce oxidative stress within cells .
    Benzydamine
  • HY-158173
    Cbl-b-IN-19

    		E1/E2/E3 Enzyme Inflammation/Immunology Cancer
    Cbl-b-IN-19 (Compound 49) is an inhibitor for casitas B-lineage lymphoma b(Cbl-b), that inhibits Cbl-b phosphorylation with an IC50 < 100 nM .
    Cbl-b-IN-19
  • HY-W268542
    4-Acetylaminoantipyrine

    		COX SOD PGE synthase Inflammation/Immunology Cancer
    4-Acetylaminoantipyrine (4-AA) is a derivative of antipyrine (HY-B0171). 4-Acetylaminoantipyrine acts as a PGE2-dependent blocker and inhibitor of cyclooxygenase (COX) . 4-Acetylaminoantipyrine can inhibit Cu/ZnSOD . 4-Acetylaminoantipyrine can spontaneously bind with bovine serum albumin (BSA) and alter its conformation .
    4-Acetylaminoantipyrine
  • HY-163476
    PIP5K1C-IN-1

    		Others Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-158166
    DNA-PK-IN-13

    		DNA-PK Inflammation/Immunology Cancer
    DNA-PK-IN-13 (Compound SK10) is a DNA-PK inhibitor that exhibits potent inhibitory activity (IC50= 0.11 nM). DNA-PK-IN-13 regulates tumor cell proliferation by decreasing the expression level of γH2A.X and enhancing the sensitivity of tumor cells to chemotherapeutic agents. DNA-PK-IN-13 is suitable for oncology studies .
    DNA-PK-IN-13
  • HY-154869
    PD-1/PD-L1-IN-34

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .
    PD-1/PD-L1-IN-34
  • HY-121278
    Benzotript

    Benzotriptum

    		 Cholecystokinin Receptor Inflammation/Immunology Cancer
    Benzotript (Benzotriptum) is a cholecystokinin-receptor (CCK) and gastrin receptor antagonist. Benzotript shows antiproliferative effects in human colon carcinoma cell lines .
    Benzotript
  • HY-14952
    Giripladib

    PLA-695

    		 Phospholipase Inflammation/Immunology Cancer
    Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteoarthritis and breast cancer research .
    Giripladib
  • HY-10404
    Dilmapimod
    1 Publications Verification

    SB-681323; GW 681323

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod
  • HY-101572
    MHP

    Methyl caprooyl tyrosinate

    		 SphK Inflammation/Immunology Cancer
    MHP (Methyl caprooyl tyrosinate) is an activator of sphingosine kinase (SPHK1), and significantly stimulates CAMP mRNA and protein production. MHP (Methyl caprooyl tyrosinate) enhances antimicrobial defense and innate immunity .
    MHP
  • HY-12005
    Fingolimod hydrochloride
    35+ Cited Publications

    FTY720

    		 LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant .
    Fingolimod hydrochloride
  • HY-76474
    BAY 61-3606

    		Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606
  • HY-12067
    R406
    25+ Cited Publications

    		 Syk FLT3 Apoptosis Inflammation/Immunology Cancer
    R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
    R406
  • HY-14985
    BAY 61-3606 dihydrochloride
    5+ Cited Publications

    		 Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606 dihydrochloride
  • HY-11109
    Resatorvid
    375+ Cited Publications

    TAK-242; CLI-095

    		 Toll-like Receptor (TLR) TNF Receptor Interleukin Related Autophagy Inflammation/Immunology Cancer
    Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases .
    Resatorvid
  • HY-13038
    Fostamatinib Disodium
    10+ Cited Publications

    R788(Disodium)

    		 Syk FLT3 Inflammation/Immunology Cancer
    Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
    Fostamatinib Disodium
  • HY-A0003
    Lenalidomide
    35+ Cited Publications

    CC-5013

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Inflammation/Immunology Cancer
    Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
    Lenalidomide
  • HY-10343
    Sotrastaurin
    15+ Cited Publications

    AEB071

    		 MARCKS PKC Inflammation/Immunology Cancer
    Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .
    Sotrastaurin
  • HY-10256
    Adezmapimod
    440+ Cited Publications

    SB 203580; RWJ 64809

    		 Organoid p38 MAPK Autophagy Mitophagy Inflammation/Immunology Cancer
    Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod
  • HY-13241
    Ralimetinib dimesylate
    10+ Cited Publications

    LY2228820 dimesylate

    		 p38 MAPK Autophagy Apoptosis Inflammation/Immunology Cancer
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
    Ralimetinib dimesylate
  • HY-10320
    Doramapimod
    25+ Cited Publications

    BIRB 796

    		 p38 MAPK Raf Autophagy Inflammation/Immunology Cancer
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
    Doramapimod
  • HY-14380
    PF-3845
    1 Publications Verification

    		 FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
    PF-3845
  • HY-13018
    MRT67307
    15+ Cited Publications

    		 IKK ULK Autophagy Inflammation/Immunology Cancer
    MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively . MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells .
    MRT67307
  • HY-10074
    TPCA-1
    30+ Cited Publications

    		 IKK STAT Apoptosis Inflammation/Immunology Cancer
    TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation.
    TPCA-1
  • HY-70074
    CCG-63802
    1 Publications Verification

    		 RGS Protein Inflammation/Immunology Cancer
    CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gαo interaction, with an IC50 value of 1.9 μM .
    CCG-63802
  • HY-32736
    Triptonide
    3 Publications Verification

    NSC 165677; PG 492

    		 Wnt β-catenin Apoptosis Autophagy Inflammation/Immunology Cancer
    Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects .
    Triptonide
  • HY-11108
    R406 free base
    25+ Cited Publications

    		 Syk FLT3 Apoptosis Inflammation/Immunology Cancer
    R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
    R406 free base
  • HY-10001
    Calcipotriol
    20+ Cited Publications

    MC 903; Calcipotriene

    		 VD/VDR Inflammation/Immunology Cancer
    Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.
    Calcipotriol
  • HY-B0008
    Sulindac

    MK-231

    		 NF-κB PD-1/PD-L1 Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac
  • HY-13344
    PF-8380
    5 Publications Verification

    		 Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    PF-8380 is a potent autotaxin inhibitor with an IC50 of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.
    PF-8380
  • HY-10001A
    Calcipotriol monohydrate
    20+ Cited Publications

    		 VD/VDR Inflammation/Immunology Cancer
    Calcipotriol monohydrate is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.
    Calcipotriol monohydrate
  • HY-15294
    CZC24832

    		PI3K Inflammation/Immunology Cancer
    CZC24832 is a highly selective and potent PI3Kγ inhibitor (IC50=27 nM) with apparent dissociation constants (Kd app) of 19 nM.
    CZC24832

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: